Active Concerns Wondering Movers: Edwards Lifesciences (NYSE:EW), Broadcom (NASDAQ:AVGO)

Edwards Lifesciences Corporation (NYSE:EW) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with 6.65% to $89.30. Edwards Lifesciences Corp. (EW) said that sales for the fourth quarter 2016 are trending towards the lower end of the previously stated $750 million to $790 million guidance, hurt by lower Surgical Heart Valve Therapy or SHVT sales trending below October guidance and the impact of foreign exchange. Transcatheter Heart Valve Therapy or THVT sales for the fourth quarter are expected to be in the range of $415 million to $430 million, consistent with its October guidance.

Critical Care sales are trending consistent with guidance.During its annual investor conference in New York City, Edwards’ management will present the company’s financial guidance for 2017. Edwards expects underlying sales growth of 10 to 14 percent, or $3.0 billion to $3.4 billion. Additionally, the company expects adjusted earnings per share of $3.30 to $3.45. This includes estimated net of $0.10 per share from the pending acquisition of Valtech Cardio, and an estimated $0.08 to $0.13 per share benefit from the accounting change related to stock-based compensation. The company also expects free cash flow of $575 million to $650 million, with all guidance excluding special items. The share price of EW attracts active investors, as stock price of week volatility recorded 3.59%. The stock is going forward to its 52-week low with 23.68% and lagging behind from its 52-week high price with -26.65%.

Broadcom Limited (NASDAQ:AVGO) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it 1.28% to close at $170.71 with the total traded volume of 3.74 Million shares. Broadcom Limited (AVGO) declared that financial results for the fourth fiscal quarter and fiscal year ended October 30, 2016, and provided guidance for the first quarter of its fiscal year 2017. Net incomewas $4,136 million, an increase of 9 percent from $3,792 million in the previous quarter and an increase of 125 percent from $1,840 million in the same quarter last year.Gross margin was $2,171 million, or 52.5 percent of net revenue.

This compares with gross margin of $1,782 million, or 47.0 percent of net revenue, in the prior quarter, and gross margin of $997 million, or 54.2 percent of net revenue, in the same quarter last year.Operating expenses were $1,790 million. This compares with $2,046 million in the prior quarter and $483 million for the same quarter last year.Operating income was $381 million, or 9 percent of net revenue. This compares with operating loss of $264 million, or 7 percent of net revenue, in the prior quarter, and operating income of $514 million, or 28 percent of net revenue, in the same quarter last year. The firm has institutional ownership of 92.40%, while insider ownership included 0.10%. Its price to sales ratio ended at 6.14. AVGO attains analyst recommendation of 2.50 with week performance of 4.87%.

 

About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *